Abstract The TGF-b signaling pathway regulates cellular proliferation and differentiation. We evaluated genetic variation in this pathway, its association with breast cancer survival, and survival differences by genetic ancestry and selfreported ethnicity. The Breast Cancer Health Disparities Study includes participants from the 4-Corners Breast Cancer Study (n = 1,391 cases) and the San Francisco Bay Area Breast Cancer Study (n = 946 cases) who have been followed for survival. We evaluated 28 genes in the TGF-b signaling pathway using a tagSNP approach. Adaptive rank truncated product (ARTP) was used to test the gene and pathway significance by Native American (NA) ancestry and by self-reported ethnicity (non-Hispanic white (NHW) and Hispanic/NA). Genetic variation in the TGF-b signaling pathway was associated with overall breast cancer survival (P ARTP = 0.05), especially for women with low NA ancestry (P ARTP = 0.007) and NHW women (P ARTP = 0.006). BMP2, BMP4, RUNX1, and TGFBR3 were significantly associated with breast cancer survival overall (P ARTP = 0.04, 0.02, 0.002, and 0.04, respectively). Among women with low NA, ancestry associations were as follows: BMP4 (P ARTP = 0.007), BMP6 (P ARTP = 0.001), GDF10 (P ARTP = 0.05), RUNX1 (P ARTP = 0.002), SMAD1 (P ARTP = 0.05), and TGFBR2 (P ARTP = 0.02). A polygenic risk model showed that women with low NA ancestry and high numbers of at-risk alleles had twice the risk of dying from breast cancer as did women with high NA ancestry. Our data suggest that genetic variation in the TGF-b signaling pathway influences breast cancer survival. Associations were similar when the analyses were stratified by genetic ancestry or by self-reported ethnicity.
The TGF-b signaling pathway regulates cellular proliferation, differentiation, apoptosis, and extracellular matrix remodeling and is involved in angiogenesis and inflammatory response [1] . The TGF-b family can be divided into two signaling pathways: (1) the bone morphogenetic proteins (BMPs) and growth and differentiations factors (GDFs) and (2) the TGFbs, activins, and myostatin. Smad proteins mediate the cellular effects of the TGF-b protein family, with BMPs and GDFs acting through Smad1, Smad5, and Smad8, whereas other members of the TGF-b family act through Smad2 and Smad3 [2] . The Smad pathway is thought to be the major TGF-b signal transduction pathway [3] . The Runt-related transcription factors (RUNX), including RUNX1, RUNX2, and RUNX3, also are involved in the TGF-b signaling pathway. Studies in RUNX3 knockout mice have shown apoptotic defects in response to TGF-b; RUNX2 transgenic mice have been shown to be hypersensitive to TGF-b [4] . All three RUNX genes have been shown to bind Smads [5] [6] [7] , thus further influencing the TGF-b signaling pathway.
It is biologically plausible that alterations of the TGF-b signaling pathway may influence breast cancer prognosis given its regulatory role in angiogenesis, inflammation, and tumor growth. Although in early stages of cancer TGF-b may exhibit tumor suppressive effects, in later stages of breast cancer it appears to be pro-tumorigenic by stimulating invasion [8] . Moreover, high serum levels and high levels of expression of TGF-b and its receptors have been linked to breast cancer prognosis [9] , and the presence of phosphorylated-Smad2 has been associated with positive node status [10] . A study by de Kruijf and colleagues [8] showed that high levels of TGF-b receptor expression in conjunction with Smad expression conferred an unfavorable prognosis after breast cancer diagnosis. The RUNX transcription factors also have been proposed as influencing survival, with RUNX2 being highly expressed in cell lines that are metastatic to bone. Because of BMPs' role in bone formation, they have been examined for their involvement in metastasis to the bone after breast cancer diagnosis and disease progression [11] . Additionally, BMPs have been associated with estrogen-induced proliferation of breast cancer cells [12] . One study has shown that BMP-Smad activation is involved in the progression of estrogen receptor positive (ER?) breast cancers specifically [13] .
Incidence and mortality rates of breast cancer have been shown to vary by race and ethnicity [14, 15] . Among women in the Southwestern USA, those who are Native American (NA) have breast cancer incidence rates that are roughly one-quarter to one-third of those observed for women who are classified as non-Hispanic white (NHW). Hispanic women have breast cancer incidence rates between those of women who are NA and those of European descent. Differences in breast cancer risk factors, such as parity, do not account for these differences [16] . Exploration of differences in disease rates can utilize genetic ancestry under the assumption that biological differences stemming from genetic factors influence the carcinogenic process. On the other hand, consideration of self-reported race/ethnicity as a stratification tool can focus on unidentified cultural factors that may contribute to disparities in cancer rates and might be common across the population, irrespective of underlying genetic differences. We considered these two methods of stratification to help understand the biological and cultural contributions to breast cancer survival.
In this study, we evaluated the associations between genetic variability in the TGF-b signaling pathway and survival after diagnosis with breast cancer. We evaluated TGFb1 and its receptors, SMAD genes, BMP genes and their receptors, RUNX genes, activins and their receptors (ACVR1, ACVR2A, ACVR2B, and ACVRL1), and GDFs (GDF10 and myostatin). We evaluated associations in an admixed population of NHW and Hispanic and Native American (NA) women, giving us the capability to examine associations by genetic ancestry as well as by self-reported ethnicity. We also evaluated survival after diagnosis with breast cancer by estrogen receptor (ER) and progesterone receptor (PR) tumor type.
Methods
This analysis from the Breast Cancer Health Disparities Study includes participants with information on survival from two population-based case-control studies, the 4-Corners Breast Cancer Study (4-CBCS) that included women from Arizona, Colorado, New Mexico and Utah, and the San Francisco Bay Area Breast Cancer Study (SFBCS) [14] who completed an in-person interview and who had a blood or mouthwash sample available for DNA extraction. In the 4-CBCS, participants were between 25 and 79 years of age with a histologically confirmed diagnosis of first primary invasive breast cancer (n = 1,391) between October 1999 and May 2004 [17] . The SFBCS included women aged 35-79 years from the San Francisco Bay Area diagnosed with a first primary histologically confirmed invasive breast cancer (n = 946) between April 1997 and April 2002 [18, 19] . All participants signed informed written consent prior to participation; this study was approved by the Institutional Review Boards for Human Subjects at the University of Utah and the Cancer Prevention Institute of California.
Data harmonization
Data used as adjustment variables were harmonized across the study centers and study-specific questionnaires as previously described [14] . Women were asked to selfreport race and, with the option to report multiple categories if appropriate, i.e., NHW and Hispanic, Hispanic and NA. Women who reported any Hispanic ethnicity or NA were broadly classified as being Hispanic. Women also were classified as either pre-menopausal or postmenopausal based on responses to questions on menstrual history. Women were considered as postmenopausal if they reported either a natural menopause or if they reported taking hormone therapy (HT) and were still having periods or were at or above the ninety-fifth percentile of age for those who reported having a natural menopause (i.e., C12 months since their last period); others were classified as pre-menopausal.
Genetic data DNA was extracted from either whole blood or mouthwash samples. Whole Genome Amplification (WGA) was applied to the mouthwash-derived DNA samples prior to genotyping. Quality control results were comparable for the two DNA sources. A tagSNP approach was used to characterize variation across candidate genes. TagSNPs were selected using the following parameters; linkage disequilibrium (LD) blocks were defined using a Caucasian LD map and an r 2 = 0.8; minor allele frequency (MAF) [ 0.1; range of -1,500 bps from the initiation codon to ?1,500 bps from the termination codon; and 1 SNP/LD bin. Additionally, 104 ancestry informative markers (AIMs) were used to distinguish European and NA ancestry in the study population [14] . All markers were genotyped using a multiplexed bead array assay format based on GoldenGate chemistry (Illumina, San Diego, California). In the current analysis, we evaluated the following genes in the TGF-b signaling pathway: ACVR1 (16 SNPs), ACVR2A (6 SNPs), ACVR2B (3 SNPs), ACVRL1 (4 SNPs), BMP1 (10 SNPs), BMP2 (6 SNPs), BMP4 (4 SNPs), BMP6 (23 SNPs), BMP7 (24 SNPs), BMPR1A (9 SNPs), BMPR1B (18 SNPs), BMPR2 (8 SNPs), GDF10 (6 SNPs), MSTN (1 SNP), RUNX1 (8 SNPs), RUNX2 (17 SNPs), and RUNX3 (8 SNPs), SMAD1 (4 SNPs), SMAD2 (5 SNPs), SMAD3 (40 SNPs), SMAD4 (2 SNPs), SMAD6 (1 SNP), SMAD7 (10 SNPs), TGFb1 (2 SNPs), TGFbRI (5 SNPs), TGFb2 (1 SNP), TGFbR2 (1 SNP), and TGFbR3 (5 SNPs). Supplemental Table 1 (online) details the genes and SNPs evaluated. Genotyping was completed for 933 women from the 4-CBCS who self-identified as NHW, 412 Hispanic, eight American Indian, 14 NHW/Hispanic, 10 NHW/American Indian, 10 Hispanic/American Indian, and four NHW/Hispanic/ American Indian and for 252 women from the SFBCS self-reported being NHW and 694 who reported being Hispanic.
Tumor characteristics and survival Data on survival were available from local cancer registries that provided information on date of death or last follow-up (month and year), cause of death, and stage of disease at time of diagnosis. Survival (in months) was calculated as the difference between diagnosis date and date of death or last follow-up. Survival information was complete for each study through May of 2012. Information on cause of death was provided and was classified as breast cancer if either the primary or contributing cause of death was noted as breast cancer. SEER summary stage data were classified as local, regional, or distant. ER and PR tumor status was provided by local tumor registries which included the Utah Cancer Registry, the New Mexico Cancer Registry, the Arizona Cancer Registry, the Colorado Cancer Registry, and the Northern California Cancer Registry.
Statistical methods
The program STRUCTURE was used to compute individual ancestry for each study participant assuming two founding populations [20, 21] . A three-founding population model was assessed, but did not fit the population structure with the same level of repeatability and correlation among runs as the two founding population models. Participants were classified by level of percent NA ancestry. Assessment across categories of ancestry was done using cutpoints based on the distribution of genetic ancestry in the study control population (2,597 Hispanic/NA and 1,586 NHW controls) with the goal of creating distinct ancestry groups that had sufficient power to assess associations, especially when looking at menopausal status within admixture groups. Two strata of B28 and[28 % were used to evaluate associations by level of NA ancestry. Genetic ancestry was used as a continuous variable when included in the models to adjust for possible confounding.
Associations between SNPs and risk of dying of breast cancer were evaluated using Cox proportional hazards models to obtain multivariate hazard ratios (HR) and 95 % confidence intervals (CI) for all women and for women stratified by genetic ancestry, self-reported ethnicity (either NHW or Hispanic/NA) and by ER/PR status using SAS version 9.3 (SAS Institute, Cary, NC). We were not able to evaluate the category of ER-/PR? tumors because there were too few women available for analysis. Individuals were censored when they died of causes other than breast cancer or were lost to follow-up. All SNPs were evaluated as a co-dominant model and if initial analysis suggested too few homozygous variant carriers a dominant model was used. However, in some instances the recessive model clearly fit the data and was used to calculate risk estimates. In addition to the minimal adjustments for age, study Cancer Causes Control (2014) 25:293-307 295 center, body mass index (BMI) in the referent year, parity, and genetic ancestry models also were adjusted for SEER summary stage. ER/PR tumor status was not adjusted in these models since these markers were not associated with tumor status and survival. Further adjustment for selfreported ethnicity did not alter associations (data not shown in tables). SNP p values were based on one degree of freedom (df) Wald chi-square tests, comparing the homozygote variants with the common genotypes when the codominant model was indicated. Interactions between genetic variants and genetic ancestry, self-reported ethnicity, and ER/PR status related to survival were assessed using p values from one and two degree of freedom Wald chi-square tests, respectively. We used the adaptive rank truncated product (ARTP) method (http://dceg.cancer.gov/bb/tools/artp) that utilizes a highly efficient permutation algorithm to determine the significance of each gene and of the TGF-b signaling pathway with survival after breast cancer diagnosis [22, 23] . We permuted the breast cancer survival outcome 10,000 times in R version 3.0.1 (R Foundation for Statistical Computing, Vienna, Austria). SNP associations were assessed among the observed and permuted data in R using p values from likelihood-ratio tests comparing full Cox proportional hazards models adjusted for age, BMI in referent year, disease stage, and genetic ancestry to reduced models excluding the SNP term. We report both gene and pathway p values (P ARTP ) based on five truncation points.
A polygenic risk summary score was created to estimate the risk of mortality associated with this pathway. SNPs included in the summary score were restricted to those located on genes with a P ARTP of 0.10 or less for all women and/or for the specific ancestry strata; only those SNPs that contributed to the best fitting ARTP model were selected. The score for each SNP was based on the inheritance model with the co-dominant or additive model having a score of zero, one, or two based on the number of high-risk alleles, whereas scores of zero or two were assigned for the dominant and recessive models. At-risk alleles were assigned based on specific ancestry group risk. Risk estimates, based on varying numbers of at-risk alleles, were estimated from proportional hazards models, taking into account confounding variables as described above. Cutpoints were selected to maintain at least 10 deaths in each category. Women missing genotype data on two or more SNPs were excluded.
Results
Fifty percent of all deaths among NHW and 57 % of all deaths among Hispanic/NA women were from breast cancer ( Table 1) . Of the 1,152 women who self-reported being Hispanic or NA, 10.4 % had NA ancestry levels at or below 18 %, compared with 99 % of NHW women. The majority of women who self-reported being Hispanic or NA had over 28 % NA ancestry. Women were more likely to die if they were older at the time of diagnosis, had ER-/ PR-tumors, or were diagnosed when their tumor was at a more advanced stage. There was no statistically significant difference in survival among women who self-reported being NHW or Hispanic/NA or when categorized by level of NA ancestry.
When considering all women, genetic variation across the entire TGF-b-signaling pathway was significantly associated with breast cancer mortality (Pathway P ARTP = 0.045). When considering individual genes, we observed statistically significant associations for BMP2, BMP4, RUNX1, and TGFBR3 (Gene P ARTP = 0.04, 0.02, 0.002, and 0.04, respectively) ( Table 2 ). There were a few SNPs in other genes that also showed statistically significant associations; however, the corresponding genes did not show overall association of statistical significance as summarized by ARTP. One SNP was significantly associated with breast cancer survival for BMP1 (rs13257482), BMP2 (rs7270163), BMP6 (rs270413), BMPR1B (rs10049681), RUNX2 (rs598953), SMAD2 (rs1792658), TBFbR1 (rs6478974) and TBFbR3 (rs6678564) at the 0.05 level or less, two SNPs were associated with breast cancer survival for GDF10 (rs7093975 and rs1902724) and RUNX1 (rs1474479 and rs1883066), and three SNPs were associated for BMP4 (rs17563, rs2761887, and rs4898820). There were no significant differences in mortality by ER/ PR status for any of the genes evaluated (see online supplement table 2).
Women with low NA ancestry or who reported being NHW had a pathway P ARTP of 0.007 and 0.006, respectively, while women with higher NA ancestry or who reported having any Hispanic/NA ethnicity pathway P ARTP values of 0.18 and 0.51, respectively. A comparison of gene and SNP associations by genetic ancestry and by self-reported ethnicity is shown in Table 3 . Several genes in the pathway were associated with breast cancer survival with findings being similar when comparing women with low NA ancestry and NHW women or when comparing those women with higher NA ancestry levels and those who self-reported being Hispanic or NA. Among women with low NA ancestry, P ARTP values were significant at or below the 0.05 level for six of 12 pathway genes (Table 3) : BMP4, BMP6, GDF10, RUNX1, SMAD1, and TGFBR2. Similar associations were observed in BMP4, BMP6, GDF10, RUNX1, and SMAD1 in NHW women, although TFGBR2 was not statistically significant. In general, individual SNP p values tended to be slightly stronger for NHW women and those with higher NA ancestry. Evaluation of associations based on p values is influenced by sample size. In our study evaluation by selfreported ethnicity resulted in a slightly larger sample for those with low NA ancestry vs. NHWs and women who self-reported being Hispanic/NA versus women with high NA ancestry. This is because roughly 19 % of those who self-reported being Hispanic or NA were in the lower NA ancestry group. Thus, we compared the associations for SNPs that were different either by genetic ancestry or by self-reported ethnicity (Table 4 shows all SNPs where the p for interaction was \0.05). For the most part, associations were strikingly similar between groups, especially when looking at risk estimates within strata.
The polygenic risk model showed increasing risk of dying from breast cancer with increasing number of at-risk alleles. This increased risk was observed for each NA ancestry group (Fig. 1) although women with the highest risk of dying associated with increasing number of at-risk alleles were those with the lowest NA ancestry. It is of interest to note that among women in the lowest category of at-risk alleles, 4.5 % of those with low NA ancestry and 5.3 % of those with higher NA ancestry died from breast cancer. This is in contrast to 27 % of women with low NA ancestry and 19.8 % of those with higher NA ancestry who were in the highest category of at-risk alleles.
Discussion
In this study, we have taken a comprehensive gene and pathway approach to assess the association between genetic variations in the TGF-b signaling pathway and survival after breast cancer diagnosis. Examination of associations by both genetic ancestry and self-reported ethnicity provided insight into the potential biological basis for differences in associations. Stronger associations with the pathway were observed for those women with lower NA ancestry (P ARTP = 0.007) compared with women with higher NA ancestry (P ARTP = 0.18). Associations with genes that were most important also varied slightly by the level of NA ancestry. Among those with low NA ancestry the most significant associations were with BMPs, TGFB1 and its receptors, and RUNX1. SMAD and Activin genes had little influence on mortality overall or in specific NA ancestry groups.
Bone is the most common metastatic site for breast cancer [24] . BMPs are key factors in bone formation and thought to play a major role in bone metastasis [25] . However, the roles of BMPs are complex, with studies showing both growth promoting and inhibitory effects [26] . BMP2 has been associated with both decreased cell proliferation and promotion of invasiveness in MCF-7 breast cancer cells [27] . BMP2, BMP4, BMP6, and BMP7 have been shown to induce angiogenesis [24] . BMP7 has been shown to promote cell migration and invasion [28] and BMP7 protein expression has been associated with accelerated bone metastasis [28] . BMPRIA has been shown to prolong survival in mice by reducing invasiveness and bone metastasis [29] , whereas BMPRIB has been associated with high tumor grade and poor prognosis [30] . Thus, there is support for the hypothesis that BMPs and their receptors influence survival after diagnosis with breast cancer. Genes that seemed most important with regard to survival in our study were BMP4 and GDF10 for all women and BMP6 among women with low NA ancestry. BMP4 has been suggested as a promoter of invasive behavior although it has been shown to reduce migration and invasion [31] . GDF10 expression, through its interaction with RUNX2, has been associated with lung cancer survival [32] , although studies in breast cancer are lacking. BMP6 has been associated with estrogen-induced breast cancer cell proliferation [33, 34] and has been shown to inhibit apoptosis in breast cancer cells [35] . Associations between specific BMP-related SNPs and breast cancer prognosis have not been reported. Our data suggest the importance of genetic variation in these genes in survival after diagnosis with breast cancer, although little is known about functionality of specific SNPs associated with risk.
Genetic variation in RUNX 1 was highly associated with breast cancer survival overall and especially among women with low NA ancestry. Most studies to date have reported on RUNX2 which promotes cell migration and invasive properties leading to metastatic bone disease [36] [37] [38] . Inactivation of RUNX3 also has been associated with breast cancer progression [39] . However, a genome-wide association analysis of ER alpha showed that RUNX1 is involved in ER regulation of genes [40] . RUNX1 also has been shown to be mutated in breast cancers [41] . For the RUNX1 SNPs that were associated with survival in our study, having a variant allele was for the most part associated with increased risk (in one instance it was protective). This could indicate that lower levels of RUNX1 could subsequently impact regulation of other important genes associated with the ER or work through multiple mechanisms. While the exact mechanism can only be speculated, our finding merits replication in other studies.
TGF-b has been shown to have both tumor promoting and tumor inhibitory action [42] . Studies have shown that during tumor progression the tumor inhibitory effects are lost, whereas the tumor promoting effects remain intact [42] . Expression of TGF-bR2 has been associated with longer survival time among women with ER-tumors [42] . Some studies have shown that TGF-b1 protein levels are associated with shorter disease-free survival, especially among those with node-negative tumors [9] , whereas others have reported associations between TGFb1-expressing tumors and a greater likelihood of breast cancer recurrence [43, 44] . A study by Mu [45] found significantly higher TGF-b1 expression with the TT genotype of rs1982073, with an accompanying two-fold increase in risk of breast cancer death; the study by Zheng supported these findings [46] . We found a similar association with rs1800469 for women with higher levels of NA ancestry, but not for women with low NA ancestry. It is not clear why the association was seen only among women with higher NA ancestry. Because these women are more likely to have Table 4 Associations between genes in TGF-b signaling pathway and breast cancer survival by genetic ancestry and self-reported race/ethnicity Percent Native American ancestry Self-reported race/ethnicity ER-tumors it is possible that they are more susceptible to the effects of TGF-b. However, we did not see differences in its association with survival according to ER status. Our findings suggest that among women with higher NA ancestry, alterations in the TGF-b signaling pathway might be more relevant for breast cancer progression, perhaps due to other genetic alterations more likely to be present in the NA ancestral background, or from other unidentified nongenetic risk factors that correlate with high NA ancestry and are associated with survival. Many associations with breast cancer survival were observed, regardless of NA ancestry or ethnicity. However, as mentioned above, some associations differed by genetic ancestry with similar differences by self-reported ethnicity. While the reasons for these differences are not clear, it is known that at the population level breast cancer incidence and mortality rates vary by NA ancestry [14, 15] , suggesting a possible biological underpinning. In general the pathway, gene, and SNP associations were more significant for women who reported being NHW or who were classified as having low NA ancestry. However, in some instances associations were different between self-reported race/ethnicity and NA ancestry group. While unidentified factors associated with culture could contribute to these observations, they likely stem from genetic ancestry modifying the risk of breast cancer death associated with these genes. A logical explanation for these differences is misclassification stemming from arbitrary cut-points. Women who reported being only NHW have the lowest level of genetic ancestry which is slightly lower than that of the low NA ancestry group. Women within the highest NA ancestry group have been determined by AIMs to have the most NA ancestry. Half of the women who selfreported being Hispanic or NA in the low admixture group had admixture comparable with the NHW; however, the other half had levels higher than most of the NHW but lower than the majority of women who reported being Hispanic or NA. When looking at genetic ancestry by case and control status, cases who self-reported being Hispanic or NA were significantly (p = 0.006) more likely to be in the very low of the ancestry group than were controls. Our data suggest that evaluating the most extreme ends of the distribution of the data separates the effects associated with genetic ancestry. Although utilization of genetic ancestry markers to classify individuals is based on a set of markers measured in everyone, the cut-points selected were arbitrary and chosen to maximize power.
Misclassification by self-reported ethnicity is also possible given that some people report multiple races and may report ethnicity differentially for a myriad of reasons, especially individuals with mixed ancestry. Follow-up with some participants in the New Mexico center resulted in some people actually changing their self-reported ethnicity (personnel communication K. Baumgartner). As stated earlier, our data suggest that cases were more likely to have lower NA ancestry than controls, which corresponds to disease trends that show that women of European ancestry have higher breast cancer incidence rates than those with more NA ancestry. We have adjusted associations for known factors that could influence risk of breast cancer death and differ by race/ethnicity, i.e., BMI, although we acknowledge that other unidentified factors could be present. Given that our research is driven by the observed differences in breast cancer risk by NA ancestry, we believe that results obtained using genetic ancestry maximizes power, accurately discriminate the biological influences of NA ancestry, and are generally reinforced by our assessment associations stratified by ethnicity. While the study has several strengths, including a large population-based sample of both NHW and Hispanic/NA women to evaluate associations with survival within a targeted candidate pathway, there are also limitations. We focused the analysis on genes within the pathway rather than individual tagSNPs. However, a logical next step is to examine the tagSNPs we identified as being important and the pathway in more depth in order to identify potentially functional SNPs that could be targeted for therapy. Additionally, since tagSNPs were not based on NA populations, some important SNPs could have been missed that influence risk among those with greater NA ancestry; further evaluation of tagSNPs in NA populations is warranted. The study included women who participated in the original case-control studies, and we lack the capability to evaluate these associations among non-participants. Our analysis may not have included women with more advanced disease who may have been too sick to participate or were deceased before being contacted for the study. It is therefore possible that associations would have been stronger if women with more advanced disease had been included in the analysis. Additionally, there are limitations to our polygenic risk score. Although we utilized ARTP permutated data to identify important genes and SNPs, another dataset for validation would be desirable. It should also be recognized that the risk estimates presented could be inflated, although setting an ARTP p value of \0.10 helps mitigate this effect. Detailed treatment data were not available, although we believe that adjustment for disease stage helps to overcome this limitation. Despite these limitations, we believe that the main messages are valid. First, risk increases with increasing ''at-risk'' alleles. We found that 5 % of women in the lowest category of at-risk alleles died compared with almost 20 % of women in the highest category of at-risk alleles. Second, the risk of dying for women with low NA ancestry in the highest category of at-risk alleles is almost twice that observed for women with higher NA ancestry.
In conclusion, our data suggest that genetic variation in the TGF-b signaling pathway influences survival after breast cancer. Associations were observed for both NHW and Hispanic women, although several genes were more strongly associated among women with low NA ancestry. Our data suggest that stratification that is able to best separate the effects of genetic ancestry is the most robust when evaluating genetic risk. Future studies that confirm these findings and determine functionality of SNPs within the pathway will enhance our understanding of the TGF-b signaling pathway and hopefully help identify potential drug targets to improve breast cancer prognosis. Centers for Disease Control and Prevention National Program of Cancer Registries and additional state support. The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official view of the National Cancer Institute or endorsement by the State of California Department of Public b Fig. 1 Hazard ratios associated with number of at-risk alleles in genes as determined by the polygenic risk score in the TGF-bSignaling Pathway. 1 Includes SNPs associated with survival among all women (at-risk allele in parenthesis): BMP2 rs7270163(A); BMP4 rs17563(C), rs762642(T), rs2761887(C), rs4898820(T); GDF10 rs7093975(C), rs762454(A), rs11598444(G), rs1902725(G), rs1902 724(A); RUNX1 rs2268288(C), rs2252585(T), rs8127225(T), rs14744 79(A), rs1883066(G); TGFB1 rs1800469(T); TGFBR3 rs6678564(G). 2 Includes SNPs uniquely associated among women with 0-28 % NA ancestry (at-risk allele in parenthesis): BMP6 rs10498671(C), rs11964227(G); SMAD1 rs714195(G), rs12505085(A); TGFBR2 rs3773644(T). Among women with non-missing covariate data, 108 women missing data on one genotype are included and 15 women missing genotype data on two (12 women) or three genotypes (2 women) are excluded. 3 Includes SNPs uniquely associated among women with [28 % NA ancestry (at-risk allele in parenthesis): BMPR2 rs12621870(T); SMAD6 rs2439385(C). Among women with non-missing covariate data, 205 women missing data on one genotype are included and 20 women missing genotype data on two (19 women) or three genotypes (1 woman) are excluded. 4 Includes women alive as date of last follow-up, those lost to follow-up, and those that died of causes other than breast cancer. 
